Shares of Sanofi SA (ADR) (NYSE:SNY) ended Tuesday session in green amid volatile trading. The shares closed up +0.20 points or 0.15% at $39.38 with 1.29 billion shares getting traded. Post opening the session at $39.10, the shares hit an intraday low of $39.10 and an intraday high of $39.44 and the price vacillated in this range throughout the day. The company has a market cap of $103.08 billion and the numbers of outstanding shares have been calculated to be 1.29 Billion shares.
On Aug. 29, 2016 Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi announced detailed positive results from ODYSSEY ESCAPE, a Phase 3 trial which evaluated Praluent® (alirocumab) Injection in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH) who require regular weekly or bi-weekly apheresis treatment. The trial demonstrated that adding Praluent to existing therapy reduced LDL cholesterol by approximately 50 percent from baseline (compared to 2 percent increase for placebo). Praluent significantly reduced the need for apheresis treatment by 75 percent compared to placebo (p less than 0.0001), the primary endpoint of the study.
Apheresis is a procedure similar to kidney dialysis where bad (LDL) cholesterol is removed from the blood, and is usually reserved for high-risk patients with very high cholesterol unable to achieve their cholesterol-lowering goals on any other therapy. Despite being treated with apheresis and entering ODYSSEY ESCAPE with very high LDL cholesterol levels (4.7 millimoles/liter [mmol/L] or 181 milligrams/deciliter [mg/dL]), nearly two-thirds (63 percent) of patients treated with Praluent no longer required apheresis therapy after six weeks of receiving Praluent. At this same time point, the average LDL cholesterol level among the Praluent-treated group was 2.3 mmol/L (90 mg/dL), compared to 4.8 mmol/L (185 mg/dL) in the placebo group. European guidelines recommend LDL cholesterol target levels between 1.8-3.0 mmol/L (70-115 mg/dL), depending on cardiovascular risk.
“Findings from ODYSSEY ESCAPE suggest a role for Praluent in the overall management of patients with HeFH undergoing regular apheresis therapy, with the potential to reduce the need for burdensome apheresis treatments,” said Patrick M Moriarty, MD, Professor, Department of Internal Medicine; Director, Atherosclerosis and Lipoprotein Apheresis Center, University of Kansas Medical Center, United States. “This is a significant development in the continued investigation of this drug in HeFH patients, because it is the first clinical trial to demonstrate that Praluent reduced the frequency of apheresis therapy.”
Shares of Express Scripts Holding Company (NASDAQ:ESRX) ended Tuesday session in green amid volatile trading. The shares closed up +0.18 points or 0.25% at $72.72 with 630.22 million shares getting traded. Post opening the session at $72.54, the shares hit an intraday low of $72.28 and an intraday high of $72.92 and the price vacillated in this range throughout the day. The company has a market cap of $45.72 Billion and the numbers of outstanding shares have been calculated to be 630.22 million shares.
Express Scripts Holding Company (ESRX) announced that it will present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2016 at 1:00 p.m. Eastern Time (12:00 p.m. Central Time).
The presentation will be broadcast via the Internet and can be accessed at the Investor Relations section of Express Scripts web site at http://www.express-scripts.com. RealPlayer or Windows Media Player is needed to listen to the broadcast and free downloads of these players are available at the broadcast site. The broadcast will remain available on the Investor Relations section of Express Scripts’ website for 90 days.